Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

Melanoma Research

Volumn 22, Issue 3, 2012, Pages 244-251

  Lai, Fritz ^a,b   Jiang, Chen Chen ^a,b   Farrelly, Margaret L ^a   Zhang, Xu Dong ^a,b   Hersey, Peter ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Bim; BRAF inhibitors; In vivo; Melanoma; Splicing

Indexed keywords

B RAF KINASE INHIBITOR; BIM PROTEIN; BOSENTAN; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PACLITAXEL; PEPTIDE; PEPTIDE SRP55; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORPHOLOGY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; TUMOR BIOPSY; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOPSY; CELL PROLIFERATION; CELL SHAPE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NUCLEAR PROTEINS; OXIMES; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA-BINDING PROTEINS; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84860767885     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328353eff2     Document Type: Article

References (37)

1. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 2007; 34:532-545. (Pubitemid 350236308)
2. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010; 21 (Suppl 7):vii339-vii344.
3. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011; 12:913-922.
4. Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AMM, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009; 20:vi35-vi40.
5. Smalley KS. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 2010; 11: 699-706.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
7. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
9. Kefford R, Arkenau H, Brown P, Milward M, Infante J.R.
10. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364:772-774.
11. Poulikakos PI, Rosen N. Mutant BRAF melanomas - dependence and resistance. Cancer Cell 2011; 19:11-15.
12. Paraiso KHT, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010; 102:1724-1730.
13. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008; 68:4853-4861.
14. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-977.
15. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutationassociated gene expression signature in melanoma. Pigment Cell Res 2007; 20:216-221. (Pubitemid 46776377)
16. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011; 17:721-730.
17. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Moriceau G, Shi H, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-390.
18. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 2010; 71:7137-7140.
19. Nguyen T, Zhang XD, Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 2001; 7:966s-973s. (Pubitemid 33600952)
20. Horikawa T, Norris DA, Zekman T, Morelli JG. Effective elimination of fibroblasts in cultures of melanocytes by lowering calcium concentration in TPA depleted medium following Geneticin treatment. Pigment Cell Res 1996; 9:58-62. (Pubitemid 126478568)
21. Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of Bims. Cell Death Dis 2010; 1:e69.
22. Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E, et al. Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 2010; 17:1354-1367.
23. Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 2010; 22:1369-1378.
24. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997; 14:1635-1642. (Pubitemid 27198935)
25. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 2010; 70:6670-6681.
26. Sato S, Fujita N, Tsuruo T. Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 2004; 279:33759-33767. (Pubitemid 39063025)
27. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10:741-754.
28. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002; 420:691-695. (Pubitemid 36764503)
29. Weber A, Paschen SA, Heger K, Wilfling F, Frankenberg T, Bauerschmitt H, et al. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol 2007; 177:625-636. (Pubitemid 46799834)
30. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005; 12:1008-1014. (Pubitemid 41065418)
31. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19:1-13. (Pubitemid 40884653)
32. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109:707-718. (Pubitemid 34722267)
33. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PloS One 2008; 3:e2734.
34. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007; 20:416-426. (Pubitemid 46482365)
35. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63:5198-5202. (Pubitemid 37139827)
36. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5:e120.
37. Davison JM, Rosenbaum E, Barrett TL, Goldenberg D, Hoque MO, Sidransky D, Westra WH. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103: 788-792. (Pubitemid 40216408)